Kataoka H, Horie Y, Koyama R, Nakatsugi S, Furukawa M
Osaka Research Laboratory, Sawai Pharmaceutical Co., LTD, Japan.
Dig Dis Sci. 2000 Jul;45(7):1366-75. doi: 10.1023/a:1005560104847.
The relative risk of development of peptic ulcer with the use of nonsteroidal antiinflammatory drugs (NSAIDs) has been reported to increase when these drugs are administered in combination with steroids. We investigated the ulcerogenic potential of a combination of NSAIDs and steroids in rats and the underlying pathogenic mechanisms. Indomethacin alone produced gastric lesions, and the severity of the lesions markedly increased with concomitant administration of prednisolone. However, nimesulide, even in excessive doses, did not produce any gastric lesions, regardless of concomitant administration with prednisolone. Furthermore, we showed that the ulcerogenic potential of indomethacin administered in combination with prednisolone may be related to the induction of physiological changes, such as endogenous prostaglandin deficiency, an increase in neutrophil activation, and gastric hypermotility, by indomethacin and alteration of normal epithelial renewal by the steroid. These results suggest that the ulcerogenic potential of preferential a COX-1 inhibitor increases following concomitant administration with a steroid, whereas, nimesulide, a preferential COX-2 inhibitor, is nonulcerogenic, even when administered concomitantly with a steroid, and is therefore a clinically useful antiinflammatory agent.
据报道,非甾体抗炎药(NSAIDs)与类固醇联合使用时,发生消化性溃疡的相对风险会增加。我们研究了NSAIDs与类固醇联合使用对大鼠的致溃疡潜力及其潜在的致病机制。单独使用吲哚美辛会产生胃部病变,同时给予泼尼松龙时,病变的严重程度会显著增加。然而,尼美舒利即使大剂量使用,无论是否与泼尼松龙同时给药,都不会产生任何胃部病变。此外,我们发现,吲哚美辛与泼尼松龙联合使用的致溃疡潜力可能与吲哚美辛诱导的生理变化有关,如内源性前列腺素缺乏、中性粒细胞活化增加和胃动力亢进,以及类固醇对正常上皮更新的改变。这些结果表明,优先选择的COX-1抑制剂与类固醇联合使用时致溃疡潜力会增加,而尼美舒利,一种优先选择的COX-2抑制剂,即使与类固醇同时给药也不会致溃疡,因此是一种临床有用的抗炎药。